Treatment Regimen for Alcohol Use Disorder

Acute Alcohol Withdrawal Management

The American Association for the Study of Liver Diseases recommends benzodiazepines as the gold standard first-line treatment for alcohol withdrawal syndrome, with long-acting agents preferred for most patients due to superior protection against seizures and delirium tremens 1, 2, 3
The American College of Gastroenterology suggests using long-acting benzodiazepines for most patients as they provide better protection against seizures and delirium tremens through gradual self-tapering 1, 2, 3
The American Association for the Study of Liver Diseases recommends switching to intermediate-acting benzodiazepines in patients with advanced age, hepatic dysfunction, or severe medical comorbidities 1, 2, 3
The Journal of Hepatology suggests using symptom-triggered dosing rather than fixed-dose schedules to prevent drug accumulation while ensuring adequate symptom control 2, 3
The Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale is used to guide treatment intensity, with scores >8 indicating moderate withdrawal requiring pharmacological intervention, and scores ≥15 indicating severe withdrawal requiring aggressive treatment 2, 3

The American College of Gastroenterology recommends naltrexone 50 mg daily as first-line pharmacotherapy after acute withdrawal resolves, as it reduces return to any drinking by 5% and binge-drinking risk by 10% 4
The American Association for the Study of Liver Diseases suggests acamprosate 666 mg three times daily as an alternative to naltrexone, particularly in patients with liver disease, as it has no reported hepatotoxicity and undergoes renal excretion only 1, 4
The American College of Gastroenterology recommends baclofen 30-60 mg/day as an alternative agent for patients with cirrhosis, reducing alcohol craving and maintaining abstinence 1, 2, 4

The American Association for the Study of Liver Diseases recommends integrating alcohol use disorder treatment with medical care, combining pharmacotherapy with psychosocial support for optimal outcomes 1, 4
The American College of Gastroenterology suggests offering cognitive-behavioral therapy (CBT), motivational enhancement therapy (MET), or motivational interviewing as part of comprehensive treatment 1
The American Association for the Study of Liver Diseases recommends encouraging engagement with mutual help groups like Alcoholics Anonymous as adjunctive support 4

The American College of Gastroenterology recommends admitting to inpatient setting if patients are at risk of severe withdrawal complications, have concurrent serious physical or psychiatric disorders, or lack adequate social support or reliable supervision 4, 3
The American Association for the Study of Liver Diseases suggests outpatient management for patients with mild-to-moderate withdrawal, stable medical/psychiatric status, and adequate social support 4

The American Association for the Study of Liver Diseases recommends avoiding naltrexone or disulfiram in patients with alcoholic liver disease or cirrhosis due to hepatotoxicity risk; use acamprosate or baclofen instead 1, 4
The Journal of Hepatology suggests avoiding extension of benzodiazepine prescriptions beyond 7-14 days as this increases dependence risk, particularly in patients with alcohol use disorder who are at higher risk of benzodiazepine abuse 2, 4
The American College of Gastroenterology recommends not delaying thiamine administration in high-risk patients or those with suspected Wernicke's encephalopathy, as this can lead to irreversible neurological damage 4, 3